Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

BACKGROUND: Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are n...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheffler, Armin, Messel, Olga, Wurthmann, Sebastian, Nsaka, Michael, Kleinschnitz, Christoph, Glas, Martin, Naegel, Steffen, Holle, Dagny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333436/
https://www.ncbi.nlm.nih.gov/pubmed/32620151
http://dx.doi.org/10.1186/s10194-020-01151-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333436/
https://www.ncbi.nlm.nih.gov/pubmed/32620151
http://dx.doi.org/10.1186/s10194-020-01151-0

Ejemplares similares